Welcome to our dedicated page for Tenax Therapeutics news (Ticker: TENX), a resource for investors and traders seeking the latest updates and insights on Tenax Therapeutics stock.
Tenax Therapeutics develops clinical-stage cardiopulmonary therapies, with news centered on levosimendan and TNX-103 for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The company describes itself as a Phase 3, development-stage pharmaceutical company and reports on the LEVEL and LEVEL-2 registrational programs, intellectual property, and global development rights for levosimendan.
Recurring announcements also cover financial results, corporate updates, investor conference participation, executive appointments, and equity-based inducement grants under Nasdaq rules. These updates connect Tenax's drug-development program with governance, finance, product-development, clinical operations, and commercial-preparation activities.
Tenax Therapeutics (Nasdaq: TENX) announced a strategic review process aimed at maximizing shareholder value, supported by Roth Capital Partners. The company is developing TNX-201 and TNX-103 for pulmonary diseases, both of which are Phase 3-ready. Tenax believes its current valuation does not reflect its clinical assets' potential. The strategic evaluation may include options like a sale or merger, although no results are guaranteed. Additionally, the launch of the TNX-201 Phase 3 trial for pulmonary arterial hypertension has been postponed to 2023.
Tenax Therapeutics, Inc. (NASDAQ: TENX) announced a KOL webinar on TNX-201, an oral modified release imatinib for pulmonary arterial hypertension (PAH), scheduled for June 2, 2022, at 11:00 AM ET. Esteemed experts, including Dr. Anna Hemnes and Dr. John Ryan, will discuss TNX-201's potential role in PAH treatment and share insights from the Phase 3 IMPRES trial of imatinib. The company aims to advance TNX-201's development, affirming its commitment to addressing unmet needs in cardiovascular therapies.
Tenax Therapeutics (NASDAQ: TENX) announced the successful completion of its pharmacokinetic study for TNX-201, a modified release formulation of imatinib for treating pulmonary arterial hypertension (PAH). The new formulation significantly enhances relative bioavailability while minimizing gastric release, addressing gastrointestinal side effects. Manufacturing is underway to support the upcoming Phase 3 trial, IMPROVE, with patient enrollment expected to start in the second half of 2022.
Tenax Therapeutics, Inc. (NASDAQ: TENX) announced an agreement to issue 10,596,027 Units at $0.755 each, raising approximately $8 million. Each Unit includes a pre-funded warrant and a warrant to purchase shares of common stock. The gross proceeds will support clinical trials for levosimendan and imatinib, R&D, and general corporate purposes. Additionally, existing warrants for 9,206,120 shares will have their exercise price reduced to $0.63 and their term extended by two years, along with other warrants for 7,783,616 shares.
Tenax Therapeutics, Inc. (TENX) reported financial results for the year ended December 31, 2021, with a net loss of $32.5 million, equating to a loss of $1.58 per share, up from a loss of $9.9 million in 2020. R&D expenses surged to $25.1 million from $4.6 million, reflecting intensified efforts on their oral formulation of imatinib, TNX-201, aimed at treating pulmonary arterial hypertension (PAH). The company plans to initiate a Phase 3 study of TNX-201 in the second half of 2022. Cash reserves stood at $5.6 million, expected to last until Q2 2022.
Tenax Therapeutics (NASDAQ: TENX) will present its late-stage drug candidates, imatinib and levosimendan, at the American College of Cardiology (ACC) Scientific Sessions from April 2-4, 2022, in Washington, D.C. The presentations include insights from the HELP trial on levosimendan for pulmonary hypertension related to left heart failure and discussions on next-generation tyrosine kinase inhibitors for PAH. These sessions feature renowned experts, including Professors Barry Borlaug and Stuart Rich, highlighting important advancements in cardiopulmonary therapies.
Tenax Therapeutics (TENX) announced the appointment of Robyn Hunter to its Board of Directors, effective January 28, 2022. Hunter, an independent director with extensive experience in development-stage biotechnology, will chair the audit and compliance committee. President and CEO Christopher T. Giordano expressed optimism about her contributions as the company advances its lead candidates, TNX-201 and TNX-102, into pivotal testing. Tenax focuses on treatments for cardiovascular and pulmonary diseases with high unmet needs.
Tenax Therapeutics (TENX) announced that the USPTO granted a patent for TNX-102, its subcutaneous formulation of levosimendan, aimed at treating pulmonary hypertension related to left heart failure (PH-HFpEF). The patent, issued on January 4, 2022, extends until at least 2039, allowing for treatment claims for various health conditions beyond PH-HFpEF. This development underscores the company's commitment to address unmet medical needs in cardiovascular diseases. Tenax plans to advance TNX-102 into pivotal Phase 3 testing based on encouraging clinical trial results.
Tenax Therapeutics (TENX) announced significant updates regarding its lead product candidates, TNX-102 and TNX-201. The company received a Notice of Allowance from the USPTO for patent claims on subcutaneous levosimendan, expected to be issued in January 2022, extending coverage until 2039. Additionally, TNX-103 successfully transitioned patients from IV to oral levosimendan, demonstrating comparable efficacy and safety. Tenax plans to initiate a Phase 3 study for TNX-201 in pulmonary arterial hypertension in the second half of 2022, supported by a new Scientific Advisory Board of experts.
Tenax Therapeutics, a specialty pharmaceutical company, reported its third quarter 2021 financial results. The company is advancing its clinical programs, initiating a pharmacokinetic study for its novel imatinib formulation, with a Phase 3 trial expected to start in Q2 2022. Tenax has received FDA clearance for its IND application and published findings on levosimendan's novel mechanism. Third quarter R&D expenses rose to $1.2 million, while G&A expenses increased to $2.6 million. The net loss was $3.8 million, with $8.4 million in cash as of September 30, 2021, expected to sustain operations until Q2 2022.